Japan's Mounjaro (Tirzepatide), a long-acting GIP/GLP-1 receptor agonist for lowering cholesterol and weight loss

1
SKU: N/A
CNY¥220.00 – CNY¥780.00Price range: CNY¥220.00 through CNY¥780.00
In Stock
Add to wishlist
Compare
Free shipping on orders of CNY ¥300 or more.
Delivery within 4–7 business days.

描述

Direct Shipping from Overseas (Direct Shipping from Japan)

Manjaro Subcutaneous Injection of Ateos

Tixipentide Weight-Loss Injection

Mounjaro® Subcutaneous Injection ATEOS®
2.5 mg / 5 mg / 7.5 mg / 10 mg / 12.5 mg / 15 mg

Document Number 2499422G1024_1_11 | Company Code 530471
Revised in May 2026 (10th Edition) / Revised in September 2026 (11th Edition)

Long-acting GIP/GLP-1 receptor agonists | Chilzepatide Injection | Type 2 Diabetes

Mounjaro Weight-Loss Injection

Product Details / Acknowledgments, etc.

Japanese Standard Product Classification Code 872499
Pharmacological Classification Name Long-acting GIP/GLP-1 receptor agonists
Generic Name Tirzepatide Injection (Tirzepatide)
2.5mg Manjaro Subcutaneous Injection 2.5 mg Ateos
YJ 2499422G1024
Approved 30400AMX00420
Sales Begin April 2023
5mg Manjaro Subcutaneous Injection 5 mg, Ateos
YJ 2499422G2020
Approved 30400AMX00421
Sales Begin April 2023
7.5mg Manjaro Subcutaneous Injection 7.5 mg Ateos
YJ 2499422G3027
Approved 30400AMX00422
Sales Begin June 2023
10mg Manjaro Subcutaneous Injection 10 mg Ateos
YJ 2499422G4023
Approved 30400AMX00423
Sales Begin June 2023
12.5mg Manjaro Subcutaneous Injection 12.5 mg Ateos
YJ 2499422G5020
Approved 30400AMX00424
Sales Begin June 2023
15mg Manjaro Subcutaneous Injection 15 mg Ateos
YJ 2499422G6026
Approved 30400AMX00425
Sales Begin June 2023
Storage Instructions / Expiration Date Store at 2–8°C / 24 months
Regulatory Distinctions –
Manufacturing and Selling Yuan Eli Lilly Japan K.K.
5-1-28 Isogami-dori, Chuo Ward, Kobe City
Sales Yuan Tanabe Pharma Co., Ltd.
3-2-10 Doshomachi, Chuo Ward, Osaka City
Packaging Various sizes: 0.5 mL × 2 sets
Mailing method Direct Shipping from Overseas (Direct Shipping from Japan)
Order Fulfillment and Shipping Times After confirming payment and prescription eligibility,
Orders are typically shipped within 4 to 7 business days.

1. Product hint

Conditions for Approval: A drug risk management plan must be developed and properly implemented.

Handling Instructions: Avoid freezing; store at 2–8°C in the dark. Do not use if frozen. When storing at room temperature, keep the product in its outer packaging at a temperature not exceeding 37°C and use within 21 days.

2. Product Characteristics and Mechanism of Action (18.)

This product is an agonist of both the GIP receptor and the GLP-1 receptor; it binds to and activates both receptors, promoting insulin secretion in a glucose-concentration-dependent manner. It is a 39-amino acid peptide containing a C20 fatty acid side chain that binds to endogenous albumin, thereby prolonging its half-life and ensuring sustained action.

Pharmacological Effects (based on administration of more than 15 mg once weekly for 28 weeks, including an evaluation after titration to steady state): Reduces fasting and postprandial blood glucose levels; promotes phase 1 and phase 2 insulin secretion in response to glucose; reduces fasting and postprandial glucagon levels; increases systemic insulin sensitivity (M value); delays gastric emptying (as indicated by acetaminophen Cmax and AUC; most pronounced after the first dose, diminishing after 4 weeks of repeated administration).

3. Specifications and Properties (3.2)

All strengths are for injection: a colorless to pale yellow to pale brown, clear or slightly milky liquid. Strengths: 2.5, 5, 7.5, 10, 12.5, and 15 mg (Ateos pre-filled kits, 0.5 mL × 2 kits each).

4. Ingredient Information (3.1/19.)

3.1 Composition Chilizepatide in a single package: 2.5, 5, 7.5, 10, 12.5, and 15 mg.

Excipients (same for all strengths): disodium hydrogen phosphate heptahydrate 0.7 mg, sodium chloride 4.1 mg, hydrochloric acid q.s., sodium hydroxide q.s.

19. Generic Name: Tirzepatide (Tirzepatide) [JAN] Molecular Formula: C225H348N48O68 Molecular weight: 4813.45 Appearance: white powder.

Residues 2 and 13 are 2-methyl-Ala, and the C-terminus is an amidated Ser; 1,20-docosadienoic acid is linked to Lys at position 20 via Glu and two 8-amino-3,6-dioxooctanoic acid linkers. A synthetic peptide consisting of 39 amino acid residues.

Structural Formula

5. Indications and Usage (4./5.)

4. Efficacy or Effectiveness Type 2 Diabetes

5. This treatment should be considered only when the basic dietary and exercise therapies for diabetes have been fully implemented but have not yielded sufficient results.

6. Dosage and Administration (6./7.)

For adults, the usual maintenance dose of chizepatide is 5 mg administered subcutaneously once weekly. However, treatment should begin with 2.5 mg once weekly, and the dose should be increased to 5 mg once weekly after 4 weeks.

The dose may be adjusted as appropriate based on the patient's condition; if a 5 mg dose once weekly is insufficient, the dose may be increased by 2.5 mg at intervals of at least 4 weeks. The maximum dose is 15 mg once weekly.

  1. 7.1 Once a week; the vote must be cast on the same day of the week each week.
  2. 7.2 Missed Dose: If there are still 3 days (72 hours) or more until the next scheduled dose, administer the missed dose immediately; thereafter, continue with the original schedule. If there are less than 3 days remaining, skip this dose and wait until the originally scheduled date. When rescheduling to a different day of the week, ensure there is an interval of at least 3 days (72 hours) since the previous dose.
  3. 7.3 If the patient cannot tolerate the medication due to gastrointestinal disturbances, consider reducing the dose or delaying the dose escalation.
  4. 7.4 Dose-dependent weight loss has been observed. When increasing the dose, in addition to monitoring blood glucose control, attention must be paid to weight loss, and the decision to increase the dose should be made with caution.

7. Important Notes (8./9./10./11./20.)

8. Important Basic Precautions

  1. 8.1 This product is not an insulin substitute. Confirm insulin dependence prior to administration. There have been reports of acute hyperglycemia and diabetic ketoacidosis following a switch from insulin to a GLP-1 receptor agonist.
  2. 8.2 Monitor blood glucose and urine glucose levels regularly to assess effectiveness; if the treatment is not effective after 3 to 4 months, consider switching to a more appropriate treatment.
  3. 8.3 Long-acting formulations may continue to have an effect after discontinuation; therefore, attention must be paid to blood glucose fluctuations as well as the prevention and management of side effects.
  4. 8.4 Patients must be fully informed about the symptoms of hypoglycemia and how to manage them.
  5. 8.5 May cause hypoglycemia; exercise caution when working at heights, driving, or engaging in similar activities.
  6. Common precautions for other similar formulations: acute pancreatitis, gastrointestinal disorders / dehydration/acute kidney injury, thyroid disorders, biliary tract disorders, hypotension, self-injection training and disposal, diabetic retinopathy; must not be used in combination with other chirzepride formulations (such as Zepbound) or other GLP-1 receptor agonists; efficacy and safety when used in combination with DPP-4 inhibitors have not been established.

9. Severe gastrointestinal disorders, history of pancreatitis, predisposition to hypoglycemia, severe diabetic retinopathy, abdominal surgery/ history of intestinal obstruction, risk of aspiration under general anesthesia or deep sedation, women of childbearing potential must use contraception during treatment and for 1 month after the final dose, not to be administered to pregnant women, use during breastfeeding requires careful consideration, not tested in children, use with caution in the elderly.

10.2 Precautions for Concomitant Use Diabetes medications (increased risk of hypoglycemia, especially sulfonylureas, rapid-acting insulin secretagogues, and insulin; consider reducing the dose); Oral contraceptives (effectiveness may be reduced during initiation or the initial dose-escalation phase; delayed gastric emptying); narrow-therapeutic-index oral medications such as warfarin (delayed Tmax; monitoring required).

11.1 Serious Adverse Effects Hypoglycemia (frequency unknown); acute pancreatitis (less than 0.11 TP3T); cholecystitis (frequency unknown), cholangitis (less than 0.11 TP3T), cholestatic jaundice (frequency unknown); Allergic reactions, angioedema (frequency unknown); ileus (frequency unknown). Common: Nausea, diarrhea, loss of appetite, etc.

20. To prevent freezing, store at 2–8°C away from light; do not use if frozen. Store in the outer carton at room temperature not exceeding 30°C and use within 21 days.

Plasma concentrations in Japanese patients with type 2 diabetes (Week 32):

Plasma concentration

Cumulative incidence of major cardiovascular events (compared with dulaglutide):

Cumulative Incidence of MACE

In the cardiovascular outcomes trial, the change in HbA1c at Week 144 was: this drug, −1.80 ± 1.37 (5,530 patients); dulaglutide, −0.93 ± 1.36 (5,390 patients). The incidence of severe hypoglycemia was approximately 0.71 TP3T in both groups. Major adverse effects in the study drug group included nausea (23.31 TP3T), diarrhea (19.61 TP3T), and decreased appetite (16.01 TP3T).

8. Contraindications (2.)

  1. 2.1 Patients with a history of allergy to any of the ingredients in this product
  2. 2.2 Diabetic ketoacidosis, diabetic coma or precoma, patients with type 1 diabetes [must be treated promptly with insulin; this product should not be administered.]
  3. 2.3 Emergencies such as severe infections or surgery [Blood glucose should be managed with insulin preparations; this product is not suitable for use in these situations.]

This product must not be administered to pregnant women or women who may be pregnant. This product is a highly potent, prescription-only medication and must be used only as prescribed by a physician. Please refer to the original Japanese package insert for details.

21–26. Other Official Information

21. A drug risk management plan must be developed and implemented.

22. 2.5/5/7.5/10/12.5/15 mg Ateos, 0.5 mL each × 2 sets.

24. Eli Lilly Japan K.K. Medical Information Inquiries TEL: 0120-360-605 medical.lilly.com/jp
Tanabe Pharma Co., Ltd. Medication Consultation Center TEL: 0120-753-280

26. Manufacturer: Eli Lilly Japan K.K. / Distributor: Tanabe Pharma Co., Ltd. ®: Registered trademark

※ This page was translated by JINZE based on PMDA Package Insert 2499422G1024_1_11. It is not a substitute for a physician’s prescription or the original Japanese version.
Enter "Manjaro" in the "Package Insert Information" field on the PMDA website to search for the original version.

[Disclaimer]

  1. The information regarding medications, treatments, or health management contained in this article is compiled from international authoritative medical journals and official clinical literature, and is intended for general science and educational reference only.
  2. The indications, side effects, and contraindications of related medications may vary depending on national regulations and individual physical conditions. Do not blindly take medication on your own or change your treatment plan.
  3. The author and publishing platform assume no legal liability for any medical delays, adverse reactions, or direct or indirect losses caused by the use of the information in this article. All medical decisions should be discussed with your attending physician before being made.

Additional information

Specifications

Tixiparib 5, Tixiparib 7.5, Tixiparib 10, Tixiparib 2.5

1 review for 日本 Mounjaro 替西帕肽 Tirzepatide 长效 GIP/GLP-1 受体激动剂 降脂减重

5.00

Average of 1 review

  1. Administration –

    Nice

Add a review

Your email address will not be published. 必填欄位標示為 *

Recently viewed

Add to wishlist
5.00

Customized products, please contact customer service

CNY ¥24,126.36
Select options This product has multiple variants. The options may be chosen on the product page
Add to wishlist
5.00

Japan's Mounjaro (Tirzepatide), a long-acting GIP/GLP-1 receptor agonist for lowering cholesterol and weight loss

CNY¥220.00 CNY¥780.00Price range: CNY¥220.00 through CNY¥780.00
Select options This product has multiple variants. The options may be chosen on the product page
Add to wishlist

Semaglutide Tablets

CNY¥800.00 CNY¥2,750.00Price range: CNY¥800.00 through CNY¥2,750.00
Select options This product has multiple variants. The options may be chosen on the product page
Store
Search
Wishes
cart
Track
Account
Select currency

No products in the cart.

Copyright 2026 © JINZE. All rights reserved. |  Return and Exchange Policy  |  Privacy Policy  |  Contact us